While strong agonist glycolipid antigens like αGalCer or other Th-1 polarizing αGalCer derivatives can lead to effective anti-microbial/anti-tumor activity from activated iNKT cells, weaker agonists like endogenous glycolipids or Th-2 biasing αGalCer analogs can polarize iNKT cell responses towards Th-2. Here, NELFCD is linked to neoplasm.